Superficial Basal Cell Carcinoma
The flat pink trunk plaque with short fine telangiectasias and small erosions; the only BCC subtype where topical therapy is first-line.
In brief
Superficial BCC presents as a slowly enlarging pink to red flat or minimally elevated plaque, most often on the trunk. It accounts for roughly 25 percent of BCCs and is the only subtype where topical agents (imiquimod, 5-fluorouracil), photodynamic therapy, or cryotherapy can replace surgery. Accurate dermoscopic classification matters because misclassifying a deeper subtype as superficial leads to treatment failure. The Lallas algorithm (maple leaf-like areas plus short fine telangiectasias in the absence of arborizing vessels, ovoid nests, or ulceration) achieves 81.9 percent sensitivity and 81.8 percent specificity for sBCC.
Clinical content
01Short fine telangiectasias are the dominant vascular pattern of superficial BCC. They are short, linear, with few or no branches, and reflect telangiectatic vessels in the papillary dermis. Reiter's pooled analysis of 1590 superficial BCCs reports prevalence 60 percent, compared with 17 percent in nodular BCC. Importantly, these vessels are not arborizing: branching, large-stem, in-focus vessels point to nodular or infiltrative subtypes.
02Multiple small erosions are highly characteristic of superficial BCC, present in 43 percent of cases and reduced to roughly 10 percent in nodular and infiltrative variants. They appear as small brown-red to brown-yellow crusts representing thin crusts overlying superficial epidermal loss. Lallas' multivariate analysis showed they make sBCC roughly 7.8-fold more likely.
03Shiny white-red structureless areas form the background of most superficial BCCs, present in 79 percent of cases. The translucent, opaque-to-red appearance reflects diffuse dermal fibrosis or fibrotic tumor stroma. Combined with leaf-like or spoke-wheel structures, this background is one of the only dermoscopic patterns that is relatively specific for the superficial subtype.
04Pigmented features when present in superficial BCC reflect melanin at the dermoepidermal junction or in small basaloid nests. Maple leaf-like areas (translucent brown to grey-blue peripheral bulbous extensions, prevalence 25 percent), spoke-wheel areas (radial brown-tan projections meeting at a darker central axis, 10 percent), and concentric structures (small irregular pigmented globules with darker central area, 14 percent) are all far more frequent in superficial than nonsuperficial BCC. These structures correlate to multifocal pigmented tumor nests connected to the epidermis on histology.
05Reflectance confocal microscopy of superficial BCC shows cords of basaloid cells connected to the epidermis, often with peripheral palisading and a thin layer of clefting. In Longo's 2014 series, cords connected to the epidermis were present in 66 percent of sBCCs and gave a 25-fold higher odds of superficial diagnosis. Streaming of the epidermis (focally elongated and distorted keratinocytes) appeared in 50 percent of sBCCs but is less specific. Collagen surrounding the cords (73 percent) supports the diagnosis but is also present in other subtypes.
06Treatment of low-risk superficial BCC offers multiple nonsurgical options. Imiquimod 5 percent cream applied 5 days per week for 6 weeks gives 78 to 80 percent clearance at 5 years (Geisse 2004; Quirk 2010). Topical 5-fluorouracil 5 percent cream gives 68 percent 3-year clearance, slightly inferior to imiquimod (Roozeboom 2016). Methyl aminolevulinate or aminolevulinic acid PDT yields 86 percent complete clearance with better cosmesis than surgery (Wang 2015 meta-analysis). Standard excision with 4 mm margins remains the gold standard with 5-year recurrence under 5 percent.
07Differential diagnosis with Bowen disease is the most common pitfall. Both present as flat pink scaly plaques, but Bowen tends to show glomerular or coiled vessels arranged in clusters, yellow scale, and a sharp border without leaf-like areas. Superficial BCC shows short fine telangiectasias, small erosions, leaf-like areas, and shiny white-red background. Papageorgiou (2018) found leaf-like areas, multiple blue-grey dots, and shiny white-red areas favor sBCC, while glomerular vessels and yellow scale favor Bowen disease.
Key dermoscopic features
High yield clinical points15 pearls in 5 groups
Recognition & pattern analysis
6 pointsDiagnostic criteria & thresholds
2 pointsManagement & treatment
3 pointsPitfalls & mimics
3 pointsWhen to biopsy
1 pointLectures covering this topic2 lectures
Notable updates & conceptual milestones5 updates
Handheld RCM for sBCC subtype assessment in the clinic
2024Longo 2024 confirmed that handheld RCM in 1005 prospectively enrolled lesions identifies cords connected to the epidermis as the strongest sBCC predictor (54-fold higher odds in adjusted analysis). Real-time bedside subtyping reduces the need for diagnostic biopsy.
Topical imiquimod 5-year SINS trial follow-up
2017The SINS randomized trial (Williams 2017) reported 82.5 percent 5-year clinical success for imiquimod vs 97.7 percent for SSEPME in 501 patients with sBCC and nBCC. Cosmetic outcomes were significantly better for imiquimod, supporting its use in low-risk patients prioritizing cosmesis.
Bowen vs sBCC dermoscopic algorithm
2018Papageorgiou (2018) developed a dermoscopic algorithm differentiating sBCC from Bowen disease using leaf-like areas, multiple blue-grey dots, glomerular vessels, and yellow scale. Useful when both diagnoses are on the differential for a flat pink scaly plaque.
Erbium:YAG laser-assisted PDT
2016Two RCTs (Smucler 2008, Choi 2016) showed that erbium:YAG laser ablative pretreatment before aminolevulinic acid or methyl aminolevulinate PDT improves clearance rates in sBCC and thin nodular BCC by enhancing photosensitizer penetration.
Step sectioning unmasks aggressive subtypes
2017Nguyen (2017) showed that 22 percent of biopsies initially diagnosed as sBCC contain a more aggressive subtype on deeper step sectioning. Reinforces the value of dermoscopy and RCM for upfront subtype prediction.
Bottom line
The flat pink trunk plaque with short fine telangiectasias and small erosions; the only BCC subtype where topical therapy is first-line.
15 clinical points · 5 recent updates · 9 references
References
Sources cited in the lecture content or that underpin the clinical points above. Verify with primary sources before practice changes.
- [1]Lallas A, Tzellos T, Kyrgidis A, et al. Accuracy of dermoscopic criteria for discriminating superficial from other subtypes of basal cell carcinoma. J Am Acad Dermatol. 2014;70(2):303-311.PubMed: 24268309DOI: 10.1016/j.jaad.2013.10.003· Foundational diagnostic algorithm for sBCC; quantifies leaf-like areas (5.9-fold) and short fine telangiectasias (4.9-fold) as positive predictors.
- [2]Longo C, Lallas A, Kyrgidis A, et al. Classifying distinct basal cell carcinoma subtype by means of dermatoscopy and reflectance confocal microscopy. J Am Acad Dermatol. 2014;71(4):716-724.e1.PubMed: 24928709DOI: 10.1016/j.jaad.2014.04.067· Cords connected to epidermis are the most specific RCM feature for sBCC (54-fold higher odds).
- [3]Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722-733.PubMed: 15097956DOI: 10.1016/j.jaad.2003.11.066· Pivotal phase III trials of topical imiquimod establishing FDA approval for sBCC.
- [4]Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614-619.PubMed: 27932240DOI: 10.1016/j.jid.2016.10.019· 5-year outcomes confirming imiquimod inferior to surgery but with better cosmesis.
- [5]Roozeboom MH, Arits AHMM, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs imiquimod vs fluorouracil for treatment of superficial basal cell carcinoma. J Invest Dermatol. 2016;136(8):1568-1574.PubMed: 27113429DOI: 10.1016/j.jid.2016.03.043· RCT comparing PDT, imiquimod, and 5-FU for sBCC at 3 years.
- [6]Reiter O, Mimouni I, Dusza S, Halpern AC, Leshem YA, Marghoob AA. Dermoscopic features of basal cell carcinoma and its subtypes: a systematic review. J Am Acad Dermatol. 2021;85(3):653-664.PubMed: 31706938DOI: 10.1016/j.jaad.2019.11.008· Pooled prevalence of sBCC features across 1590 cases.
- [7]Papageorgiou C, Apalla Z, Variaah G, et al. Accuracy of dermoscopic criteria for the differentiation between superficial basal cell carcinoma and Bowen's disease. J Eur Acad Dermatol Venereol. 2018;32(11):1914-1919.PubMed: 29633377DOI: 10.1111/jdv.14995· Discriminating algorithm for the most common sBCC differential diagnosis.
- [8]Nguyen KP, Knuiman GJ, van Erp PE, Blokx WA, Gerritsen MJP. Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes. J Am Acad Dermatol. 2017;76(2):351-353.e3.PubMed: 28088999DOI: 10.1016/j.jaad.2016.07.046· 22 percent of sBCC biopsies hide an aggressive component on step sectioning.
- [9]Verkouteren BJA, Nelemans PJ, Sinx KAE, et al. Imiquimod Cream Preceded by Superficial Curettage vs Surgical Excision for Nodular BCC. JAMA Dermatol. 2025;161(3):299-304.PubMed: 39878970DOI: 10.1001/jamadermatol.2024.5572· 5-year RCT: surgery 98.2% vs curettage plus imiquimod 77.8% free of treatment failure for nodular BCC; non-surgical option reasonable when surgery declined.